We serve Chemical Name:2-Fluoro-4-pyridinamine CAS:18614-51-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:2-Fluoro-4-pyridinamine
CAS.NO:18614-51-2
Synonyms:2-Fluoro-4-pyridinamine;MFCD03095284;4-Amino-2-fluoropyridine;4-Pyridinamine, 2-fluoro-;2-Fluoropyridin-4-amine
Molecular Formula:C5H5FN2
Molecular Weight:112.105
HS Code:2933399090
Physical and Chemical Properties:
Melting point:N/A
Boiling point:264.0±20.0 °C at 760 mmHg
Density:1.3±0.1 g/cm3
Index of Refraction:1.554
PSA:38.91000
Exact Mass:112.043678
LogP:0.77
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:
Contact us for information like 2-Fluoro-4-pyridinamine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Fluoropyridin-4-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Fluoro-4-pyridinamine Use and application,4-Amino-2-fluoropyridine technical grade,usp/ep/jp grade.
Related News: For category of products which involve fermentation technologies, incentive is 20 per cent of the approved sales price. The government has put a cap of Rs. 10 crore per product per annum for five years. This is a seven year scheme from 2023-24 going up to 2029-30. 2-methyl-2-(4-methylsulfanyl-6-trimethylsilanylamino-[1,3,5]triazin-2-ylamino)-propionic acid trimethylsilanyl ester manufacturers This announcement follows earlier expansions at the Ballina site where additional Good Manufacturing Practice (GMP) facilities and capabilities have been added in analytical, cell culture, vaccine support and other specialised Biologics services. 5-(2-((1-isopropylpyrrolidin-3-yl)oxy)-4-(trifluoromethyl)phenyl)-2-ureidothiophene-3-carboxamide suppliers SARS-CoV-2 has evolved mutations that severely compromise the neutralizing activities of multiple IgG monoclonal antibodies, including those under clinical trials and authorized for emergency use.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 10a-Hydroxy-3,4,4a,10a-tetrahydro-1H-dibenzo-p-dioxinon-(2) vendor & factory.
Therefore, developing new antibody therapies that can overcome these challenges is an urgent unmet need, and we are pleased with the data published today,” An said.
“Synergizing the strengths of multiple institutions from academia and industry is the key to the rapid translation from ideas to therapeutic candidates.
This is another example of such success. The cross-institutional and academic-industry collaborations should be expanded to other disease indications,” said Pei-Yong Shi, PhD, professor and co-senior author of the study from the Department of Biochemistry and Molecular Biology at UTMB Health.
This antibody has been licensed to biotech partner IGM Biosciences for drug development.
“The ability to use potently neutralizing IgM antibodies against SARS-CoV-2 with broad coverage of VOCs, VOIs, and viral escape mutants, is a very exciting application of the IGM platform,” said Fred Schwarzer, CEO of IGM Biosciences.
“We are grateful to our collaborators at UTHealth, UTMB Health, and our scientists at IGM for the exceptional work described in Nature today. 10a-Hydroxy-3,4,4a,10a-tetrahydro-1H-dibenzo-p-dioxinon-(2) vendor & factory.
